Leqembi, produced by Eisai and Biogen, is not a cure for Alzheimer’s but significantly slows down cognitive decline. It ...

Lecanemab was approved in the U.S. in 2023 as the world's first drug to slow the cognitive decline associated with Alzheimer's. The treatment also has received approval in Japan, China, Europe and ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Awards Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesLOS ANGELES, May 08, 2025 (GLOBE ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...